CD8A and neoplasm: A very recent study has shown that both tumor cells and immune cells secret PD-L1-positive sEVs into circulation, while only PD-L1-positive sEVs from tumor cells and CD8 T cells predict clinical outcome of treatment41, suggesting that the heterogeneity in cellular origin would significantly affect the accuracy of sEV PD-L1-based liquid biopsy.